April 17th 2024
Patients who responded positively to shunt treatment experienced more beneficial changes in their heart's structure and function compared with nonresponders.
Addressing Disparities Starts With Engaging the Community
September 24th 2021In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.
Read More
Reducing Disparities, Using AI, Improving Clinical Trials on Tap for PCOC 2021
September 17th 2021At the 10th anniversary meeting of Patient-Centered Oncology Care®, sessions will cover reducing disparities in cancer care, bringing clinical trials closer to the community, and expanding the scope of what the term "precision medicine" means in cancer care.
Read More
Could Psychedelics Ease Mental Health Toll From COVID-19, Other Crises?
September 15th 2021The fallout from COVID-19 has spotlighted the limitations of US mental health care, prompting the question if alternative treatments—like psychedelics—could help address current and impending crises.
Read More
The Green Environment, Air Pollution, and Respiratory Health
September 9th 2021Increasing air pollution and climate change have an impact on respiratory health and mortality, explained speakers in 2 sessions on the environment and respiratory diseases at the European Respiratory Society International Congress 2021.
Read More
Considering Sex and Gender Differences in Respiratory Health
September 7th 2021Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.
Read More
Disparities Persist in the Long Term for 5-Year AYA Survivors of Hodgkin Lymphoma
August 4th 2021Treatment-related modifications have resulted in improved long-term outcomes for all adolescent and young adult (AYA) survivors of Hodgkin lymphoma, but new research highlights that racial, ethnic, and socioeconomic status disparities persist in the long term.
Read More
Dr Ron Eccles Outlines the Challenges of the Placebo Effect for Cough Medicines
July 24th 2021Patients may find a placebo effect beneficial, but it causes issues in a clinical trial and makes it difficult to understand the efficacy of a pharmacological agent, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.
Watch
NAFLD Increases Mortality in Children and Young Adults Over the Long Term
July 8th 2021A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.
Read More
Identifying Surrogate End Points for PFS in Newly Diagnosed Multiple Myeloma
June 25th 2021Minimal residual disease, overall response rate, complete response rate, and stringent complete response may be useful as surrogate end points to estimate progression-free survival (PFS) benefit for patients with newly diagnosed multiple myeloma.
Read More
OTC Drugs Don't Target Chronic Cough Mechanisms, Dr Jacky Smith Explains
June 13th 2021OTC cough medicines may have some temporary benefit, but they don't penetrate the nerves in the airways, which are believed to be the mechanism behind refractory chronic cough, says Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust.
Watch
The Large Placebo Effect in Cough Presents Major Challenges for Antitussive Trials
June 12th 2021New antitussive trials are challenged by large placebo effects and the risk of the trial being unblinded due to adverse effects, explained Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.
Read More
Dr Ron Eccles Discusses the Placebo Effect in Chronic Cough Clinical Trials
June 11th 2021The placebo effect is a major problem in cough trials and can make it impossible to tell the true pharmacological effect of the medicine being studied, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.
Watch
Zanubrutinib Improves Outcomes Compared With Ibrutinib in R/R CLL/SLL, ALPINE Study Shows
June 11th 2021An interim analysis of the phase 3 ALPINE study demonstrated that zanubrutinib has a superior response rate, improved progressive-free survival, and lower rate of atrial fibrillation/flutter compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL).
Read More
Dr Jacky Smith Discusses Key Research Abstracts at the American Cough Conference
June 11th 2021Desensitizing the cough reflex and new technologies based on artificial intelligence are some of the oral abstracts that Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust, who chairs that session, is looking forward to at the American Cough Conference.
Watch
Clinical Trial Results Need to Be Supplemented With Real-World Data in Multiple Myeloma
June 11th 2021The populations represented in randomized controlled trials often do not match the populations being treated in the real world due to eligibility criteria, which can be challenging when translating those results to real-world decisions, explained speakers during a session at the European Hematology Association 2021 Virtual Congress.
Read More
Dr Bijal Shah on the Toxicity in Phase 2 of ZUMA-3
June 11th 2021The phase 2 ZUMA-3 trial of brexucabtagene autoleucel showed that it is possible to intervene early to prevent some toxicity, said Bijal Shah, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center.
Watch
“Practice-Changing” Results Seen for Pembrolizumab in Adjuvant Setting in Renal Cell Carcinoma
June 7th 2021The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.
Read More
After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?
May 26th 2021Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.
Read More